<DOC>
	<DOCNO>NCT01588639</DOCNO>
	<brief_summary>This prospective , multi-center , open-label , non-interventional , 12-week study people type 2 diabetes mellitus treat recombinant human insulin-SciLin N , SciLin R SciLin M30 ( alone combination ) routine clinical practice . The term study insulin use protocol drug combination .</brief_summary>
	<brief_title>To Evaluate Clinical Outcome Injection Compliance Scilin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Based physician ' clinical judgement , subject treat SciLin N , SciLin R SciLin M30 ( alone combination ) eligible include clinical study . Subjects one condition list exclude : Women pregnant , breast feeding intention become pregnant within next 6 month Subjects treat insulin simultaneously Subjects participate diabetes clinical study time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Recombinant human insulin</keyword>
	<keyword>T2DM</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>